A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)
Status:
Terminated
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase III, multicenter, global, clinical study of an investigational drug called
galiximab in combination with an approved drug called rituximab in subjects with follicular
NHL.
The purpose of the study is to compare the clinical benefit of galiximab when given in
combination with rituximab as compared with rituximab alone (given with placebo) in subjects
with follicular NHL. Safety and pharmacokinetics (PK) of galiximab and rituximab will also be
evaluated.